This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John M. Jessup, MD; Glenn Steele, Jr, MD; Robert J. Mayer, MD; Marshall Posner, MD; Paul Busse, MD; Blake Cady, MD; Michael Stone, MD; Roger Jenkins, MD; Robert Osteen, MD

Arch Surg. 1993;128(5):559-564.

Abstract
• The purposes of this study were to determine whether continuous infusion of fluorouracil combined with externalbeam radiation therapy improved the resectability and survival of patients with pancreatic carcinoma. Sixteen patients with unresectable disease confined to the pancreas and celiac nodes were treated, and their outcome was compared with that of 24 patients with potentially resectable disease who were treated concurrently. The neoadjuvant therapy was completed with acceptably few toxic effects but with only a minor decrease in tumor size. Two patients underwent resection and remained free of disease 20 and 22.5 months later. However, the median survival of the entire neoadjuvant group was 8 months. All 24 patients with potentially resectable carcinoma underwent surgical exploration. Fifteen of the 24 patients underwent resection and survived a median of 12.5 months. Neoadjuvant chemoradiation may have improved outcome and resectability for two (12.5%) of 16 patients with unresectable pancreatic carcinoma, but more effective therapy options must be developed to improve outcome.

(Arch Surg. 1993;128:559-564)

Author Affiliations
From the Departments of Surgery (Drs Jessup, Steele, Cady, Stone, and Jenkins) and Medicine (Dr Posner), New England Deaconess Hospital, the Dana-Farber Cancer Institute (Dr Mayer), the Joint Center for Radiation Therapy (Dr Busse), and Department of Surgery, Brigham and Women's Hospital (Dr Osteen), Boston, Mass.

Footnotes
Accepted for publication January 30, 1993.

Reprint requests to 110 Francis St, Suite 3-A, Boston, MA 02215 (Dr Jessup).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Locally Advanced Pancreatic Cancer
Willett et al.
JCO 2005;23:4538-4544.
ABSTRACT | FULL TEXT  

Treatment of Pancreatic Cancer Cells with Dicumarol Induces Cytotoxicity and Oxidative Stress
Lewis et al.
Clin. Cancer Res. 2004;10:4550-4558.
ABSTRACT | FULL TEXT  

Dicumarol Inhibition of NADPH:Quinone Oxidoreductase Induces Growth Inhibition of Pancreatic Cancer via a Superoxide-mediated Mechanism
Cullen et al.
Cancer Res. 2003;63:5513-5520.
ABSTRACT | FULL TEXT  

Suppression of the Malignant Phenotype in Human Pancreatic Cancer Cells by the Overexpression of Manganese Superoxide Dismutase
Weydert et al.
Molecular Cancer Therapeutics 2003;2:361-369.
ABSTRACT | FULL TEXT  

Pancreatic Cancer: Local Success and Distant Failure
Ryan and Grossbard
The Oncologist 1998;3:178-188.
ABSTRACT | FULL TEXT  

Assessment of Resectability of Pancreatic Head and Periampullary Tumors by Color Flow Doppler Sonography
Wren et al.
Arch Surg 1996;131:812-818.
ABSTRACT